Between 1999 and 2018, the pharmaceutical and health products industry spent $4.7 billion lobbying the federal government — an average of $233 million per year — according to a study published in JAMA Internal Medicine by Wouters and colleagues in 2020. The same study documented $414 million in presidential and congressional campaign contributions and $877 million directed to state-level candidates. These are staggering sums, but they represent only the most visible layer of an influence operation that extends deep into the regulatory apparatus itself. The more consequential channel of influence is the revolving door between government health agencies and the pharmaceutical industry — a pipeline so well-established that it has become a structural feature of American drug regulation rather than an aberration.
A Harvard study on the Department of Health and Human Services found that nearly one-third of political appointees left for private sector roles after their government service. At the Centers for Disease Control and Prevention, the asymmetry was even more striking: only eight percent of officials came from the private sector, but 54 percent left for industry positions. The FDA’s revolving door has produced a steady stream of former officials who have landed at Eli Lilly, Pfizer, Merck, Roche, Novartis, and United Therapeutics, according to reporting by STAT News. The career incentive is unmistakable: a mid-career regulator who maintains good relations with the industry they oversee can expect a substantial compensation increase upon transitioning to a corporate role, while one who takes an adversarial approach risks foreclosing that option.
The Money Pipeline
The 2024 election cycle illustrated the bipartisan nature of pharmaceutical influence. Industry PACs and employees directed $26.4 million to Democrats and $16.1 million to Republicans, according to OpenSecrets data. Seventy-two of 100 U.S. senators received at least $10,000 from pharmaceutical interests, with twelve senators — seven Democrats and five Republicans — exceeding $100,000. The average pharmaceutical contribution to Senate campaigns was $69,000 for Democrats and $50,000 for Republicans; in the House, the figures were $47,000 and $45,000 respectively. The industry’s financial reach is not partisan but comprehensive, ensuring that regardless of which party controls the regulatory apparatus, pharmaceutical companies maintain access to the decision-makers who determine drug approval timelines, pricing policies, and enforcement priorities.
The Roosevelt Institute has described the pharmaceutical industry as “the epitome of regulatory capture” — a characterization that the industry’s defenders dismiss but that the structural evidence supports. Regulatory capture occurs when an agency created to act in the public interest instead advances the commercial interests of the industry it regulates. In pharmaceuticals, this dynamic manifests not through dramatic corruption but through the gradual alignment of regulatory culture with industry perspectives: deference to company-sponsored clinical trial data, reluctance to pursue enforcement actions that might disrupt market access, and a career framework that treats industry employment as the natural culmination of government service rather than a potential conflict of interest.
The State-Level Dimension
While federal lobbying receives the most attention, the pharmaceutical industry’s state-level influence is equally significant and considerably less scrutinized. The National Institute on Money in Politics tracks pharmaceutical contributions to gubernatorial candidates, state legislators, state supreme court justices, and party committees across all 50 states. State health boards, pharmacy boards, and insurance regulators make decisions that directly affect drug pricing, formulary composition, and market access — decisions that are made with far less public visibility than their federal counterparts and by officials who are even more susceptible to industry influence due to smaller campaign finance ecosystems and lower media scrutiny.
The consequences of this regulatory architecture are felt most directly by patients. Drug pricing in the United States remains the highest in the developed world, a reality that persists despite decades of political promises to address it. The industry’s lobbying expenditures and campaign contributions have been remarkably effective at blocking or diluting every meaningful pricing reform that has reached the legislative process. The Inflation Reduction Act’s Medicare drug price negotiation provisions — limited to a small number of drugs and phased in over years — represent the first significant breach in the industry’s legislative defenses, and they were achieved only after decades of failed attempts.
The revolving door is not illegal, and many of the individuals who pass through it bring genuine expertise to both their government and industry roles. But the cumulative effect of a system in which regulators anticipate future employment by the entities they regulate is a regulatory culture that systematically favors industry interests over public health. Until Congress imposes meaningful cooling-off periods, restricts the scope of post-government employment in regulated industries, and creates compensation structures that make career government service financially competitive with industry positions, the revolving door will continue to spin — and the American public will continue to pay the price in higher drug costs and weaker regulatory oversight.